Empagliflozin & Linagliptin DIABETES INDICATION Emlino (Empagliflozin and Linagliptin) is indicated for use in combination with metformin as an adjunct to diet and exercise, to achieve glycemic control in adult patients with type 2 diabetes mellitus (T2DM) who are: • inadequately controlled on metformin and empagliflozin, or • inadequately controlled on metformin and linagliptin or […]
Empagliflozin & LinagliptinSGLT2 Inhibitor & DPP-4 Inhibitor Combination (Antidiabetic Preparations) Indication: GlympaTM is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. Dosage & Administration: […]